| General Information | |
|---|---|
| ZINC ID | ZINC000073170230 |
| Molecular Weight (Da) | 439 |
| SMILES | CCCCCc1cc(O)cc(OCCCCCCCCCCC(=O)OC(CO)CO)c1 |
| Molecular Formula | C25O6 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 122.43 |
| HBA | 6 |
| HBD | 3 |
| Rotatable Bonds | 20 |
| Heavy Atoms | 31 |
| LogP | 6.277 |
| Activity (Ki) in nM | 5623.41 |
| Polar Surface Area (PSA) | 96.22 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | - |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | - |
| Thyroid receptor binding | - |
| Androgen receptor binding | + |
| Plasma protein binding | 0.75494349 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 6 |
| Fraction csp3 | 0.72 |
| Ilogp | 4.83 |
| Xlogp3 | 6.26 |
| Wlogp | 4.91 |
| Mlogp | 3.08 |
| Silicos-it log p | 6.39 |
| Consensus log p | 5.09 |
| Esol log s | -5.33 |
| Esol solubility (mg/ml) | 0.00207 |
| Esol solubility (mol/l) | 0.00000472 |
| Esol class | Moderately |
| Ali log s | -8.07 |
| Ali solubility (mg/ml) | 0.00000375 |
| Ali solubility (mol/l) | 8.55E-09 |
| Ali class | Poorly sol |
| Silicos-it logsw | -6.9 |
| Silicos-it solubility (mg/ml) | 0.0000551 |
| Silicos-it solubility (mol/l) | 0.00000012 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.53 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 1 |
| Veber number of violations | 1 |
| Egan number of violations | 0 |
| Muegge number of violations | 2 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 3 |
| Synthetic accessibility | 3.81 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -4.393 |
| Logd | 3.997 |
| Logp | 5.973 |
| F (20%) | 0.998 |
| F (30%) | 0.996 |
| Mdck | - |
| Ppb | 96.77% |
| Vdss | 0.657 |
| Fu | 1.32% |
| Cyp1a2-inh | 0.413 |
| Cyp1a2-sub | 0.156 |
| Cyp2c19-inh | 0.394 |
| Cyp2c19-sub | 0.052 |
| Cl | 9.59 |
| T12 | 0.866 |
| H-ht | 0.054 |
| Dili | 0.033 |
| Roa | 0.012 |
| Fdamdd | 0.054 |
| Skinsen | 0.946 |
| Ec | 0.003 |
| Ei | 0.081 |
| Respiratory | 0.044 |
| Bcf | 1.054 |
| Igc50 | 5.303 |
| Lc50 | 4.679 |
| Lc50dm | 4.169 |
| Nr-ar | 0.561 |
| Nr-ar-lbd | 0.003 |
| Nr-ahr | 0.111 |
| Nr-aromatase | 0.443 |
| Nr-er | 0.604 |
| Nr-er-lbd | 0.006 |
| Nr-ppar-gamma | 0.928 |
| Sr-are | 0.435 |
| Sr-atad5 | 0.006 |
| Sr-hse | 0.867 |
| Sr-mmp | 0.949 |
| Sr-p53 | 0.838 |
| Vol | 474.595 |
| Dense | 0.924 |
| Flex | 2.857 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 0 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | - |
| Toxicophores | 1 |
| Qed | 0.21 |
| Synth | 2.47 |
| Fsp3 | 0.72 |
| Mce-18 | 8 |
| Natural product-likeness | 0.717 |
| Alarm nmr | 1 |
| Bms | 1 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |